EQS-News: HepaRegeniX GmbH / Key word(s): Personnel HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor 23.11.2022 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor Tübingen (Germany), November 2.
HepaRegeniX Appoints Elias Papatheodorou as New Chairman of the Board of Directors saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
TUBINGEN, GERMANY / ACCESSWIRE / March 30, 2022 / HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy | Small Molecules pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.